Caption Management’s Corcept Therapeutics CORT Stock Holding History

Caption Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-260,000	Closed	-$15.7M	–	1728
2026 Q1	$10.5M	Buy	+260,000	New	+$9.72M	0.06%	320
2025 Q4	–	Sell	-34,000	Closed	-$2.67M	–	1646
2025 Q3	$2.83M	Buy	+34,000	New	+$2.46M	0.02%	706
2024 Q2	–	Sell	-27,000	Closed	-$740K	–	1215
2024 Q1	$680K	Buy	+27,000	New	+$638K	0.01%	822
2022 Q1	–	Sell	-22,800	Closed	-$485K	–	1533
2021 Q4	$451K	Buy	+22,800	New	+$462K	0.01%	1277
2021 Q2	–	Sell	-4,000	Closed	-$95K	–	1338
2021 Q1	$95K	Buy	+4,000	New	+$107K	﹤0.01%	962
2020 Q2	–	Sell	-20,000	Closed	-$281K	–	964
2020 Q1	$237K	Sell	20,000 -3,900	-16%	-$48.3K	0.01%	674
2019 Q4	$288K	Buy	+23,900	New	+$333K	0.01%	694
2019 Q3	–	Sell	-40,000	Closed	-$446K	–	739
2019 Q2	$446K	Buy	40,000 +33,100	+480%	+$369K	0.02%	496
2019 Q1	$81K	Buy	+6,900	New	+$85.7K	﹤0.01%	528

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's CORT Position: Q2 2026 in Review

Caption Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 260,000 shares — an estimated $15.7M sold.

Caption Management first reported a position in CORT in Q1 2019 and held it in 9 quarters. The position peaked at $10.5M in Q1 2026. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Caption Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 260,000 Corcept Therapeutics shares in Q2 2026, an estimated $15.7M.
Caption Management first reported a position in Corcept Therapeutics in Q1 2019 and held it in 9 quarters.
Caption Management's Corcept Therapeutics position peaked at $10.5M in Q1 2026.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.